The implementation of sublobar resection in treating early-stage non-small cell lung cancer (NSCLC) showed “comparable oncologic outcomes and complication rates” compared to lobectomy across a variety of clinical trials, according to a systematic review of the surgical technique. Robert E. Merritt, MD, of The Ohio State University Wexner Medical Center in Columbus, Ohio, and a team of colleagues conducted the review, which was published in Seminars in Thoracic and Cardiovascular Surgery. ...
Lung Cancers Today
A new medical news property for practicing oncologists treating lung malignancies, Lung Cancers Today features breaking news, commentary, expert interviews, and more.
Advertisement
The FDA action date for its regulatory decision is anticipated during the third quarter of this year.
Dr. Liu shares his insights on the recent announcement that the phase 3 trial met its secondary endpoint of overall survival.
A team integrating clinical, dual-energy spectral computed tomography, and radiomics features into a predictive model.
The phase 2 trial included patients who had advanced or metastatic NSCLC with actionable genomic alterations.
Sunvozertinib is an irreversible EGFR inhibitor that targets a wide spectrum of EGFR mutations.
Glecirasib, also known as JAB-21822, is an oral, covalent KRAS G12C inhibitor.
For patients with NSCLC and EGFR mutations, amivantamab plus carboplatin-pemetrexed shows OS benefits versus chemo alone.
The improvement in median OS with the combination treatment is “expected to exceed one year," officials said.
The study showed there was “preliminary evidence of central nervous system-anti-tumor activity” in some patients.
The TROPiCS-03 trial, a multicohort, open-label basket study, is assessing the antibody-drug conjugate in solid tumors.
Advertisement
Roundtable Discussions on Lung Cancer
Expert Interviews on Lung Cancer
Conference Coverage
Find the latest news and updates on lung cancer from the ESMO Congress 2024.
Find the latest updates on lung cancer treatment and research from the IASLC 2024 World Conference on Lung Cancer.
Find the latest updates on lung cancer treatment and research from the 2024 ASCO Annual Meeting.
Our editors detail the latest data and innovations in the lung cancer space presented at ATS 2024.
Our editors deliver in-depth coverage of NACLC 2023, a premier event offering the latest data on lung cancer advancements.
Our editors provide comprehensive coverage of ESMO Congress 2023, with a focus on lung cancer.
Our editors detail the latest data and innovations in the lung cancer space, as presented at WCLC 2023.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.